Unit dosage forms comprising between 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, or 80 mg 1-hexadecyl-2-(4&rsquo-carboxybutyl)-glycerol-3-phosphocholine (VB-201) and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed herein, as well as treatment regimens comprising oral administration of VB-201 once or twice daily for treating an inflammatory disease or disorder selected from the group consisting of psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, atherosclerosis, an inflammation of a carotid artery, an inflammation of an aorta, colitis, ileitis, Crohn&rsquos disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, inflammatory bowel disease, celiac disease, ulcerative colitis, an ulcer, a skin ulcer, a bed sore, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, and a gastrointestinal ulcer.
